NextCure, Inc. (NXTC)

1,5300 +0,0400 (+2,68%) Al cierre: 04:00PM EDT

NextCure, Inc.

9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
United States
240 399 4900
https://www.nextcure.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 82

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Michael S. Richman MSBA	Co-Founder, CEO, President & Director	698,39k	N/A	1961
Dr. Solomon Langermann Ph.D.	Chief Scientific Officer	530,32k	N/A	1960
Dr. Han Myint FACP, M.D.	Chief Medical Officer	546,66k	N/A	1954
Dr. Lieping Chen M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	1957
Dr. Timothy Mayer Ph.D.	Chief Operating Officer	N/A	N/A	1965
Mr. Kevin G. Shaw	Senior VP & General Counsel	N/A	N/A	1975
Ms. Stacy Rollinger	Vice President of Human Resources	N/A	N/A	N/A
Mr. Sourav Kundu Ph.D.	Senior Vice President of Development & Manufacturing	N/A	N/A	1961
Dr. Sebastien Maloveste	Senior Vice President of Business Development	N/A	N/A	N/A
Dr. Udayan Guha M.D., Ph.D.	Senior Vice President of Clinical & Translational Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Gobierno corporativo

El ISS Governance QualityScore de NextCure, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 5; Tablero: 5; Derechos de los accionistas: 5; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.